Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.
about
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersAnti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targetsInhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR GammaThe interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer.Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α.Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Identifying genetic interactions associated with late-onset Alzheimer's disease.Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancerChemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemopreventionSuppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10.Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivoThe cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinomaA novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activityNovel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenograftscGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon.Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants.Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats.Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.Expression of phosphodiesterase 6 (PDE6) in human breast cancer cellsThe role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatmentNew NSAID targets and derivatives for colorectal cancer chemoprevention.COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.NSAIDs inhibit tumorigenesis, but how?Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs.Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.Inhibition of breast cancer cell migration by activation of cAMP signaling.The role of cGMP and its signaling pathways in kidney disease.Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling.Phosphodiesterase type 5 and cancers: progress and challenges.Analysis of Neuroprotection by Taurine and Taurine Combinations in Primary Neuronal Cultures and in Neuronal Cell Lines Exposed to Glutamate Excitotoxicity and to Hypoxia/Re-oxygenation.Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors.Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
P2860
Q26739665-C45DD376-4764-4230-8CDC-9688AD72CA57Q27004250-AA616D6F-E93F-4BA4-8CDF-C92530C7FCE3Q33562863-88792C28-39F5-43C7-9933-CA9FCCE58FF7Q33748280-C08AFC90-53A0-4CED-9DAA-B7ED00CDDD84Q33768672-AE03A8A3-3AD1-432A-9153-8F1B3FC18DFDQ34601724-0FFFDBF2-FBDF-42FD-A9D9-A9F4C3505017Q34662369-6EBACDED-6A29-4524-A730-D1C26C2B8D17Q34765802-F1A9825A-701C-4667-821A-D2BBCA91AD24Q34989308-43F63F64-B179-4821-89F5-1F34482EFA4EQ35021758-7949A26F-E1C0-44B0-87CE-91222A63F271Q35751821-F1CCF8A1-E21E-4B3A-8D2C-8C4B512AC1E0Q35827798-A65F8795-C75A-4864-897C-7BCEFBE36A2AQ35859243-5AB7E7EA-95D3-436E-AEFC-D528DDF45D01Q36413785-7D21A1B3-A03F-41B3-A501-481A8EE008B0Q36420145-AF24FBE1-D1CC-4E1B-88B9-E97F54065940Q36458158-E196D607-C024-4982-9C10-81D1F757B21AQ36537864-308190C9-21B1-4685-85C5-200A69383297Q36637814-F13DFC4D-EDDD-430D-8FC6-CDA9FE950335Q36752069-C8277F99-D922-43CD-909B-933944FFFAF8Q36825244-1E066EB5-3672-462D-9A8A-4867DDCA11FAQ36952021-79FD1751-A71A-4033-8DE9-5E22EBABF135Q37238527-79285B75-4FF1-4736-9188-ED0921B6A80AQ37417720-820E9CCB-C852-4413-8967-4FC7435AE989Q37426831-35B8BBFB-6CCD-4288-984D-EE7E2519E6C6Q37668627-4F4A24F1-E257-4C29-80FC-47C13F5187EAQ37693485-61AF54EA-AC79-455A-BA74-B92C35CAAD13Q38034670-89248B3A-8C09-454C-8BAE-ACEA6902558DQ38123175-FE6C4E06-A23B-48B8-AE05-9D2AA979D493Q38169133-D3468E81-AFF0-4FEF-841A-83D8CCB5E87CQ38554955-0E420662-9EE5-473D-BDB1-387CFE2C97AFQ38724210-A4C66B1C-1592-4FC1-B639-608957C0F555Q38786791-4EBBC0B5-0C44-4E76-951C-EE881BE62D1CQ38837269-2B6363A8-48BA-4588-9A70-128FBFB9E589Q38869800-DDA5093C-BE55-46A7-992E-55849CFAFAF4Q38896087-1BC026ED-34F5-491E-B8A2-4C215ACF3A1FQ42378330-FE2A8B00-1789-45B3-827D-E2A25355BB76Q47171803-6BE5CA0B-B67C-4FD4-A378-C75FF8DFE26CQ48136027-DB1BF094-2840-468F-B35D-03E5DFEC2679Q54301069-83293A53-B393-4096-AF9A-F773CBC5EBC2Q55457391-AAD984F4-2624-413C-A9F8-848F962EEDA3
P2860
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@ast
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@en
type
label
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@ast
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@en
prefLabel
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@ast
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@en
P2093
P2860
P1476
Inhibition of PDE5 by sulindac ...... n in human breast tumor cells.
@en
P2093
Adam B Keeton
Bernard D Gary
Gary A Piazza
Heather N Tinsley
P2860
P304
P356
10.1158/1940-6207.CAPR-11-0095
P577
2011-04-19T00:00:00Z